Haydom Lutheran Hospital
Babati, Manyara Region, Tanzania
NCT Number: NCT04172012
This study examines the effect of oral probiotic treatment to newborns on preventing hospitalizations, death and colonization with Extended-spectrum beta-lactamase-producing Gram negative bacteria. Half of the babies will receive 4 weeks treatment with an oral mixture of the probiotic Labinic (R) while the other half will receive a placebo mixture.
Looking for future studies?
Notify MeUp to 3 day
All sexes
Interventional
Phase 3
Babati, Manyara Region, Tanzania
Studies show that probiotics given to prematurely born babies prevents sepsis and is widely used in the western world for this purpose. Probiotics consists of one or more normal gut-bacteria. A large study in India showed that giving probiotics to full-born babies reduced hospitalizations and morbidity. This study investigates giving a probiotic mixture with different combination of bacteria, Lactobacillus acidophilus, Bifidobacterium infantis and Bifidobacterium breve, for a longer duration (4 weeks instead of 7 days).
Infections with antibiotic-resistant bacteria is a major threat to health-care world-wide, and sepsis/severe infection caused by such bacteria is a major cause of neonatal death. The study hypothesis is that giving probiotics to newborns prevents them from getting colonized with antibiotic-resistant bacteria, such as Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). By preventing colonization with ESBL-PE, severe infections such as sepsis may be prevented, and thereby survival may be improved.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Labinic (R) probiotic mixture containing Lactobacillus acidophilus and Bifidobacterium infantis and B. breve
Placebo mixture
Time frame: 6 months from inclusion
Primary outcome is hospitalization and/or death of study subject
Time frame: 6 weeks and 6 months
Faecal colonisation with Extended-spectrum beta-lactamase-producing Enterobacteriaceae as detected by fecal swab
Time frame: 6 weeks and 6 months
Hospitalisation
Time frame: 6 months
Death during study period
Time frame: 6 months
Growth monitored by weight
Time frame: 6 months
Growth monitored by length
Time frame: 6 weeks and 6 months
Stool microbiota composition including resistome analysis (metagenome sequencing)
Time frame: 6 weeks and 6 months
Stool metabolome composition
Time frame: 6 weeks and 6 months
Levels of Calprotectin in participants' stool samples
Time frame: 6 weeks and 6 months
Levels of alpha-1 antitrypsin (AAT) in participants' stool samples
Time frame: 6 weeks and 6 months
Levels of human myeloperoxidase (MPO) in participants' stool samples
Time frame: 6 months
Bacteremia confirmed by blood culture
Time frame: 6 weeks and 6 months
Genetic characteristics of ESBL-E from colonization and clinical samples (targeted screening)
Haydom Lutheran Hospital
Other
Use of Probiotics to Reduce Infections and Death and Prevent Colonization With Extended-spectrum Beta-lactamase Producing Bacteria, Among Newborn Infants in Haydom and Surrounding Area, Tanzania, a Randomized Controlled Clinical Trial
Acronym: ProRIDE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07245277
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Bandung, West Java, Indonesia
View Trial DetailsNCT05856227
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases
Evanston, Illinois, United States
View Trial DetailsNCT05730387
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Vancouver, British Columbia, Canada
View Trial DetailsNCT03871491
COVID-19, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Dhaka, Bangladesh
View Trial Details